In this issue:
Combined TNFi/methotrexate therapy increases likelihood of joint remission
Increased risk of anterior uveitis with secukinumab and etanercept vs monoclonal TNFi
Efficacy of a tight-control/treat-to-target strategy in axSpA
Women have worse axSpA disease burden and more peripheral symptoms
Tofacitinib effective in real-world for refractory PsA
Predictors of clinical response to certolizumab pegol in non-radiographic axSpA
Central sensitisation, illness perception and obesity impact disease activity in axSpA
Methotrexate ineffective for maintenance of TNFi-induced remission in peripheral SpA
Fundamental lack of awareness and knowledge regarding axSpA in UK physios
Worse COVID-19 outcomes in patients with autoimmune inflammatory rheumatic diseases
Please login below to download this issue (PDF)